Stockscreener 앱 받기
172.48
1.67%
2.84
시장 영업 전:
174.26
1.78
+1.03%
전일 마감가:
$169.64
열려 있는:
$170.695
하루 거래량:
4.74M
Relative Volume:
2.10
시가총액:
$267.50B
수익:
$60.48B
순이익/손실:
$10.40B
주가수익비율:
51.80
EPS:
3.3297
순현금흐름:
$8.05B
1주 성능:
+1.85%
1개월 성능:
-8.45%
6개월 성능:
+85.02%
1년 성능:
+140.12%
1일 변동 폭
$170.67
$174.44
1주일 범위
$166.04
$174.44
52주 변동 폭
$72.57
$212.71
아스트라제네카 ADR Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
172.48 | 263.09B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,220.66 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
266.73 | 640.91B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
263.20 | 453.91B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
131.82 | 322.95B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
159.85 | 296.72B | 54.66B | 13.58B | 16.05B | 7.0171 |
아스트라제네카 ADR Stock (AZN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-27 | 개시 | Citigroup | Buy |
| 2025-10-27 | 재개 | Jefferies | Buy |
| 2025-10-16 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2025-04-15 | 개시 | Exane BNP Paribas | Outperform |
| 2025-02-13 | 업그레이드 | UBS | Neutral → Buy |
| 2025-02-12 | 개시 | Morgan Stanley | Overweight |
| 2024-11-20 | 업그레이드 | UBS | Sell → Neutral |
| 2024-11-06 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-09-13 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-16 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-02-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Sell |
| 2024-01-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-09-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-07-12 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-05 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-04-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2022-09-15 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | 업그레이드 | Argus | Hold → Buy |
| 2022-06-14 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-11 | 업그레이드 | DZ Bank | Sell → Hold |
| 2021-12-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-12 | 재개 | JP Morgan | Overweight |
| 2021-04-12 | 다운그레이드 | Argus | Buy → Hold |
| 2021-03-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-25 | 업그레이드 | UBS | Neutral → Buy |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-12-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | 업그레이드 | UBS | Sell → Neutral |
| 2020-11-11 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2019-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-10-25 | 업그레이드 | Liberum | Hold → Buy |
| 2019-04-02 | 다운그레이드 | UBS | Neutral → Sell |
| 2019-02-05 | 개시 | Exane BNP Paribas | Outperform |
| 2019-01-25 | 업그레이드 | Shore Capital | Hold → Buy |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-08-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-03-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-02-06 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-05 | 재확인 | Bernstein | Outperform |
| 2018-01-18 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-12-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-10-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
모두보기
아스트라제네카 ADR 주식(AZN)의 최신 뉴스
Judge Dismisses AstraZeneca’s Bid To Stop Maine Pharmacy Law - Bloomberg Law News
AstraZeneca's drug pipeine is splitting opinion among City analysts - Proactive Investors
ASTRAZENECA : DZ Bank gives a Buy rating - marketscreener.com
ASTRAZENECA : Gets a Buy rating from Berenberg - marketscreener.com
ASTRAZENECA : Gets a Buy rating from Goldman Sachs - marketscreener.com
ASTRAZENECA : UBS remains its Buy rating - marketscreener.com
AstraZeneca reports Phase III results for Ultomiris and Sone-Ve - Clinical Trials Arena
AstraZeneca Stock: What We Thought of Earnings - Morningstar
AstraZeneca Kept at Buy as Berenberg Notes 'Upbeat' Q2 Earnings Call - marketscreener.com
AstraZeneca PLC (AZN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
AZN Q2 FY2026 earnings call - finance.biggo.com
AstraZeneca PLC (AZN) Stock Forecasts - Yahoo Finance
AstraZeneca PLC (AZN) Q2 2026 Earnings Call Highlights: Strong Oncology and Rare Disease Growth ... - Yahoo Finance
AZN Q2 Earnings and Sales Beat, Key Drugs Offset Generic Pressure - TradingView
AstraZeneca’s MONTEROSA Study Tracks Real World Outcomes for STRIDE in Liver Cancer - TipRanks
AstraZeneca: Q2 2026 Results Were All Right, But Farxiga Poses Risks (NYSE:AZN) - Seeking Alpha
AstraZeneca PLC (AZN) Investigation: Bronstein, Gewirtz & Grossma - The National Law Review
AstraZeneca rallies Monday, outperforms market - MarketWatch
AstraZeneca PLC (AZN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
AstraZeneca quarterly net profit rises 2% on strong cancer drug sales - Yahoo Finance UK
Astrazeneca Rises on Profit Beat; Paramount Pauses WBD Deal | Stock Movers - marketscreener.com
AstraZeneca: In line Q2; correction of late is an entry point - marketscreener.com
Dow Jumps Over 400 Points; AstraZeneca Shares Rise After Q2 Earnings - Benzinga
AstraZeneca drug prices evolving in response to Trump policy, executive says - Reuters
AstraZeneca PLC Stock Analysis: Q2 Earnings Beat vs Bearish Trend - The Cryptonomist
Astrazeneca (AZN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
AstraZeneca says adjusting drug pricing over Trump policies By Investing.com - Investing.com Nigeria
Astrazeneca Q2 Earnings Call Highlights - Yahoo Finance
What's Going on With AstraZeneca Stock Monday?AstraZeneca (NYSE:AZN) - Benzinga
AstraZeneca (NASDAQ: AZN) lifts H1 profit and backs 2026 outlook - Stock Titan
AstraZeneca oncology growth continues despite product setback - Investors' Chronicle
AstraZeneca profit rises on strong cancer drug sales - Yahoo Finance
AstraZeneca Sees 2030 Goal on Track as Cancer Drugs Drive Growth - WSJ
ASTRAZENECA : Jefferies gives a Buy rating - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages AstraZeneca PLC (AZN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Mixed Ultomiris HSCT-TMA results at AstraZeneca (NASDAQ: AZN) spur paediatric filings - Stock Titan
AstraZeneca PLC 2026 Q2ResultsEarnings Call Presentation (NYSE:AZN) 2026-07-27 - Seeking Alpha
AstraZeneca to Acquire Worldwide Rights to Lung Cancer Drug for $600M - Stock Titan
AstraZeneca sales boosted by soaring demand for cancer treatments - Yahoo Finance UK
AstraZeneca (NASDAQ: AZN) Phase III Sone-Ve data show gastric survival gain - Stock Titan
ASTRAZENECA PLC ORD SHS $0.25 (AZN.L) Q2 FY2026 earnings call transcript - Yahoo Finance
AstraZeneca stock edges up on earnings beat despite revenue miss - Investing.com
AstraZeneca Q2 Core Earnings, Revenue Rise; Interim Dividend Raised - marketscreener.com
AstraZeneca PLC Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
AstraZeneca reiterates guidance after topping Q2 profit expectations; shares up - Investing.com Nigeria
AstraZeneca PLC (AZN) Stock Analysis: Exploring a 26% Potential Upside and Strong Buy Ratings - DirectorsTalk Interviews
Market Open: Vodafone raises guidance, AstraZeneca H1 growth - Yahoo Finance UK
AstraZeneca CFO says AI is not expected to lead to job cuts - marketscreener.com
AstraZeneca sales rise as demand for cancer treatments grow - Yahoo Finance UK
AstraZeneca Logs Higher First-half Profit on Strong Oncology, Rare Disease Drugs Sales; Outlook Maintained - marketscreener.com
AstraZeneca’s Cancer Medicines Spur Profit Growth - Bloomberg
아스트라제네카 ADR (AZN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.40%
자본화:
|
볼륨(24시간):